Raras
Buscar doenças, sintomas, genes...
Deficiências combinadas de hormônios hipofisários, formas genéticas
ORPHA:95494CID-10 · E23.0CID-11 · 5A61.0DOENÇA RARA

O hipopituitarismo congênito é caracterizado por deficiência múltipla de hormônio hipofisário, incluindo deficiências somatotróficas, tireotróficas, lactotróficas, corticotróficas ou gonadotróficas, devido a mutações de fatores de transcrição hipofisários envolvidos na ontogênese hipofisária. O hipopituitarismo congênito é raro em comparação com a alta incidência de hipopituitarismo induzido por adenomas hipofisários, cirurgia transesfenoidal ou radioterapia.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

O hipopituitarismo congênito é caracterizado por deficiência múltipla de hormônio hipofisário, incluindo deficiências somatotróficas, tireotróficas, lactotróficas, corticotróficas ou gonadotróficas, devido a mutações de fatores de transcrição hipofisários envolvidos na ontogênese hipofisária. O hipopituitarismo congênito é raro em comparação com a alta incidência de hipopituitarismo induzido por adenomas hipofisários, cirurgia transesfenoidal ou radioterapia.

Publicações científicas
270 artigos
Último publicado: 2026 Mar 19

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Início
Infancy
+ neonatal
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: E23.0
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

📏
Crescimento
36 sintomas
🦴
Ossos e articulações
13 sintomas
👁️
Olhos
10 sintomas
😀
Face
10 sintomas
🧠
Neurológico
9 sintomas
🫃
Digestivo
6 sintomas

+ 59 sintomas em outras categorias

Características mais comuns

100%prev.
Hipopituitarismo
55%prev.
Hipogonadismo hipogonadotrófico
Frequente (79-30%)
55%prev.
Hipotensão
Frequente (79-30%)
55%prev.
Osteopenia
Frequente (79-30%)
55%prev.
Resposta diminuída ao teste de estímulo do hormônio do crescimento
Frequente (79-30%)
55%prev.
Nível anormal de prolactina
Frequente (79-30%)
161sintomas
Muito frequente (1)
Frequente (18)
Ocasional (6)
Muito raro (14)
Sem dados (122)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 161 características clínicas mais associadas, ordenadas por frequência.

HipopituitarismoHypopituitarism
Muito frequente100%
Hipogonadismo hipogonadotróficoHypogonadotropic hypogonadism
Frequente (79-30%)55%
HipotensãoHypotension
Frequente (79-30%)55%
Osteopenia
Frequente (79-30%)55%
Resposta diminuída ao teste de estímulo do hormônio do crescimentoDecreased response to growth hormone stimulation test
Frequente (79-30%)55%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2025
Total histórico270PubMed
Últimos 10 anos21publicações
Pico20244 papers
Linha do tempo
2025Hoje · 2026📈 2024Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

20 genes identificados com associação a esta condição. Padrão de herança: Autosomal dominant, Autosomal recessive, X-linked recessive.

PROP1Homeobox protein prophet of Pit-1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Possibly involved in the ontogenesis of pituitary gonadotropes, as well as somatotropes, lactotropes and caudomedial thyrotropes

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

Pituitary hormone deficiency, combined, 2

Combined pituitary hormone deficiency is defined as the impaired production of growth hormone and one or more of the other five anterior pituitary hormones. CPHD2 is characterized by pleiotropic deficiencies of growth hormone, thyroid-stimulating hormone, follicle-stimulating hormone, luteinizing hormone, prolactin and adrenocorticotropic hormone.

EXPRESSÃO TECIDUAL(Baixa expressão)
Pituitária
2.0 TPM
Cerebelo
0.3 TPM
Cérebro - Hemisfério cerebelar
0.3 TPM
Testículo
0.1 TPM
Próstata
0.0 TPM
OUTRAS DOENÇAS (4)
pituitary hormone deficiency, combined, 2combined pituitary hormone deficiencies, genetic formhypothyroidism due to deficient transcription factors involved in pituitary development or functionpanhypopituitarism
HGNC:9455UniProt:O75360
PROKR2Prokineticin receptor 2Candidate gene tested inTolerante
FUNÇÃO

Receptor for prokineticin 2. Exclusively coupled to the G(q) subclass of heteromeric G proteins. Activation leads to mobilization of calcium, stimulation of phosphoinositide turnover and activation of p44/p42 mitogen-activated protein kinase

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
G alpha (q) signalling eventsPeptide ligand-binding receptors
MECANISMO DE DOENÇA

Hypogonadotropic hypogonadism 3 with or without anosmia

A disorder characterized by absent or incomplete sexual maturation by the age of 18 years, in conjunction with low levels of circulating gonadotropins and testosterone and no other abnormalities of the hypothalamic-pituitary axis. In some cases, it is associated with non-reproductive phenotypes, such as anosmia, cleft palate, and sensorineural hearing loss. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In the presence of anosmia, idiopathic hypogonadotropic hypogonadism is referred to as Kallmann syndrome, whereas in the presence of a normal sense of smell, it has been termed normosmic idiopathic hypogonadotropic hypogonadism (nIHH).

EXPRESSÃO TECIDUAL(Baixa expressão)
Testículo
0.7 TPM
Brain Frontal Cortex BA9
0.3 TPM
Córtex cerebral
0.2 TPM
Brain Anterior cingulate cortex BA24
0.1 TPM
Hipocampo
0.1 TPM
OUTRAS DOENÇAS (5)
hypogonadotropic hypogonadism 3 with or without anosmiapituitary stalk interruption syndromeKallmann syndromehypogonadotropic hypogonadism
HGNC:15836UniProt:Q8NFJ6
SOX2Transcription factor SOX-2Candidate gene tested inAltamente restrito
FUNÇÃO

Transcription factor that forms a trimeric complex with OCT4 on DNA and controls the expression of a number of genes involved in embryonic development such as YES1, FGF4, UTF1 and ZFP206 (By similarity). Binds to the proximal enhancer region of NANOG (By similarity). Critical for early embryogenesis and for embryonic stem cell pluripotency (PubMed:18035408). Downstream SRRT target that mediates the promotion of neural stem cell self-renewal (By similarity). Keeps neural cells undifferentiated by

LOCALIZAÇÃO

Nucleus speckleCytoplasmNucleus

VIAS BIOLÓGICAS (10)
Formation of the posterior neural plateDeactivation of the beta-catenin transactivating complexInterleukin-4 and Interleukin-13 signalingGerm layer formation at gastrulationTranscriptional regulation of pluripotent stem cells
MECANISMO DE DOENÇA

Microphthalmia, syndromic, 3

A disease characterized by the rare association of malformations including uni- or bilateral anophthalmia or microphthalmia, and esophageal atresia with trachoesophageal fistula. Microphthalmia is a disorder of eye formation, ranging from small size of a single eye to complete bilateral absence of ocular tissues (anophthalmia). In many cases, microphthalmia/anophthalmia occurs in association with syndromes that include non-ocular abnormalities.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Amígdala
69.8 TPM
Brain Caudate basal ganglia
68.0 TPM
Brain Nucleus accumbens basal ganglia
67.1 TPM
Brain Anterior cingulate cortex BA24
66.8 TPM
Brain Frontal Cortex BA9
57.5 TPM
OUTRAS DOENÇAS (4)
anophthalmia/microphthalmia-esophageal atresia syndromemicrophthalmia, isolated, with colobomananophthalmiaseptooptic dysplasia
HGNC:11195UniProt:P48431
ARNT2Aryl hydrocarbon receptor nuclear translocator 2Candidate gene tested inRestrito
FUNÇÃO

Transcription factor that plays a role in the development of the hypothalamo-pituitary axis, postnatal brain growth, and visual and renal function (PubMed:24022475). Specifically recognizes the xenobiotic response element (XRE)

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (6)
NPAS4 regulates expression of target genesXenobioticsPhase I - Functionalization of compoundsAryl hydrocarbon receptor signallingEndogenous sterols
MECANISMO DE DOENÇA

Webb-Dattani syndrome

A disorder characterized by postnatal microcephaly with fronto-temporal lobe hypoplasia, multiple pituitary hormone deficiency, global developmental delay, seizures, severe visual impairment and abnormalities of the kidneys and urinary tract.

OUTRAS DOENÇAS (2)
Webb-Dattani syndromeseptooptic dysplasia
HGNC:16876UniProt:Q9HBZ2
ELF4ETS-related transcription factor Elf-4Candidate gene tested inAltamente restrito
FUNÇÃO

Transcriptional activator that binds to DNA sequences containing the consensus 5'-WGGA-3'. Transactivates promoters of the hematopoietic growth factor genes CSF2, IL3, IL8, and of the bovine lysozyme gene. Acts synergistically with RUNX1 to transactivate the IL3 promoter (By similarity). Transactivates the PRF1 promoter in natural killer (NK) cells and CD8+ T cells (PubMed:34326534). Plays a role in the development and function of NK and NK T-cells and in innate immunity. Controls the proliferat

LOCALIZAÇÃO

Nucleus, PML body

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
48.1 TPM
Sangue
41.3 TPM
Baço
32.4 TPM
Pulmão
31.2 TPM
Fibroblastos
28.8 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (2)
autoinflammatory syndrome, familial, X-linked, Behcet-like 2short stature due to isolated growth hormone deficiency with X-linked hypogammaglobulinemia
HGNC:3319UniProt:Q99607
FGFR1Fibroblast growth factor receptor 1Candidate gene tested inAltamente restrito
FUNÇÃO

Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of embryonic development, cell proliferation, differentiation and migration. Required for normal mesoderm patterning and correct axial organization during embryonic development, normal skeletogenesis and normal development of the gonadotropin-releasing hormone (GnRH) neuronal system. Phosphorylates PLCG1, FRS2, GAB1 and SHB. Ligand binding leads to the activati

LOCALIZAÇÃO

Cell membraneNucleusCytoplasm, cytosolCytoplasmic vesicle

VIAS BIOLÓGICAS (2)
Epithelial-Mesenchymal Transition (EMT) during gastrulationFormation of paraxial mesoderm
MECANISMO DE DOENÇA

Pfeiffer syndrome

A syndrome characterized by the association of craniosynostosis, broad and deviated thumbs and big toes, and partial syndactyly of the fingers and toes. Three subtypes are known: mild autosomal dominant form (type 1); cloverleaf skull, elbow ankylosis, early death, sporadic (type 2); craniosynostosis, early demise, sporadic (type 3).

EXPRESSÃO TECIDUAL(Ubíquo)
Aorta
144.8 TPM
Ovário
142.9 TPM
Artéria tibial
134.1 TPM
Fallopian Tube
122.3 TPM
Cérebro - Hemisfério cerebelar
122.0 TPM
OUTRAS DOENÇAS (20)
Hartsfield-Bixler-Demyer syndromeencephalocraniocutaneous lipomatosisosteoglophonic dysplasiaPfeiffer syndrome
HGNC:3688UniProt:P11362
TBX19T-box transcription factor TBX19Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Transcriptional regulator involved in developmental processes. Can activate POMC gene expression and repress the alpha glycoprotein subunit and thyroid-stimulating hormone beta promoters

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

ACTH deficiency, isolated

An autosomal recessive disorder that is characterized by adrenal insufficiency symptoms, such as weight loss, lack of appetite (anorexia), weakness, nausea, vomiting and low blood pressure (hypotension). The pituitary hormone ACTH is decreased or absent, and other cortisol and other steroid hormone levels in the blood are abnormally low.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
77.7 TPM
Útero
17.7 TPM
Aorta
13.1 TPM
Ovário
11.3 TPM
Cervix Ectocervix
9.8 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (1)
congenital isolated adrenocorticotropic hormone deficiency
HGNC:11596UniProt:O60806
GHRHRGrowth hormone-releasing hormone receptorDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Receptor for GRF, coupled to G proteins which activate adenylyl cyclase. Stimulates somatotroph cell growth, growth hormone gene transcription and growth hormone secretion

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
G alpha (s) signalling eventsGlucagon-type ligand receptors
MECANISMO DE DOENÇA

Growth hormone deficiency, isolated, 4

An autosomal recessive deficiency of growth hormone leading to early and severe growth failure and short stature. Patients have low but detectable levels of growth hormone, significantly retarded bone age, and a positive response and immunologic tolerance to growth hormone therapy.

EXPRESSÃO TECIDUAL(Tecido-específico)
Pituitária
294.2 TPM
Testículo
0.3 TPM
Hipotálamo
0.3 TPM
Brain Anterior cingulate cortex BA24
0.3 TPM
Cerebelo
0.2 TPM
OUTRAS DOENÇAS (1)
isolated growth hormone deficiency, type 4
HGNC:4266UniProt:Q02643
BTKTyrosine-protein kinase BTKDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Non-receptor tyrosine kinase indispensable for B lymphocyte development, differentiation and signaling (PubMed:19290921). Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation (PubMed:19290921). After BCR engagement and activation at the plasma membrane, phosphorylates PLCG2 at several sites, igniting the downstream signaling pathway through calcium mobilization, followed by activation of the protein kinase C (PKC) family members (P

LOCALIZAÇÃO

CytoplasmCell membraneNucleusMembrane raft

VIAS BIOLÓGICAS (10)
Antigen activates B Cell Receptor (BCR) leading to generation of second messengersPotential therapeutics for SARSMyD88:MAL(TIRAP) cascade initiated on plasma membraneER-Phagosome pathwayIRAK4 deficiency (TLR2/4)
MECANISMO DE DOENÇA

X-linked agammaglobulinemia

Humoral immunodeficiency disease which results in developmental defects in the maturation pathway of B-cells. Affected boys have normal levels of pre-B-cells in their bone marrow but virtually no circulating mature B-lymphocytes. This results in a lack of immunoglobulins of all classes and leads to recurrent bacterial infections like otitis, conjunctivitis, dermatitis, sinusitis in the first few years of life, or even some patients present overwhelming sepsis or meningitis, resulting in death in a few hours. Treatment in most cases is by infusion of intravenous immunoglobulin.

OUTRAS DOENÇAS (3)
isolated growth hormone deficiency type IIIBruton-type agammaglobulinemiashort stature due to isolated growth hormone deficiency with X-linked hypogammaglobulinemia
HGNC:1133UniProt:Q06187
RNPC3RNA-binding region-containing protein 3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Participates in pre-mRNA U12-dependent splicing, performed by the minor spliceosome which removes U12-type introns. U12-type introns comprises less than 1% of all non-coding sequences. Binds to the 3'-stem-loop of m(7)G-capped U12 snRNA

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
mRNA Splicing - Minor Pathway
MECANISMO DE DOENÇA

Pituitary hormone deficiency, combined or isolated, 7

An autosomal recessive deficiency of growth hormone characterized by severe postnatal growth failure, delayed bone age without bone dysplasia, and hypoplasia of the anterior pituitary.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
78.9 TPM
Tireoide
78.1 TPM
Cerebelo
61.3 TPM
Ovário
58.9 TPM
Cervix Endocervix
58.3 TPM
OUTRAS DOENÇAS (2)
isolated growth hormone deficiency, type 5isolated growth hormone deficiency type IA
HGNC:18666UniProt:Q96LT9
SOX3Transcription factor SOX-3Disease-causing germline mutation(s) inModerado
FUNÇÃO

Transcription factor required during the formation of the hypothalamo-pituitary axis. May function as a switch in neuronal development. Keeps neural cells undifferentiated by counteracting the activity of proneural proteins and suppresses neuronal differentiation. Required also within the pharyngeal epithelia for craniofacial morphogenesis. Controls a genetic switch in male development. Is necessary for initiating male sex determination by directing the development of supporting cell precursors

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
Deactivation of the beta-catenin transactivating complex
MECANISMO DE DOENÇA

Panhypopituitarism X-linked

Affected individuals have absent infundibulum, anterior pituitary hypoplasia, and ectopic posterior pituitary.

EXPRESSÃO TECIDUAL(Tecido-específico)
Testículo
5.6 TPM
Pituitária
3.0 TPM
Hipotálamo
2.9 TPM
Brain Nucleus accumbens basal ganglia
1.6 TPM
Brain Spinal cord cervical c-1
1.4 TPM
OUTRAS DOENÇAS (7)
intellectual disability, X-linked, with panhypopituitarismpanhypopituitarism, X-linkedX-linked intellectual disability with isolated growth hormone deficiencyseptooptic dysplasia
HGNC:11199UniProt:P41225
ROBO1Roundabout homolog 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Receptor for SLIT1 and SLIT2 that mediates cellular responses to molecular guidance cues in cellular migration, including axonal navigation at the ventral midline of the neural tube and projection of axons to different regions during neuronal development (PubMed:10102268, PubMed:24560577). Interaction with the intracellular domain of FLRT3 mediates axon attraction towards cells expressing NTN1 (PubMed:24560577). In axon growth cones, the silencing of the attractive effect of NTN1 by SLIT2 may re

LOCALIZAÇÃO

Cell membraneCell projection, axonEndoplasmic reticulum-Golgi intermediate compartment membrane

VIAS BIOLÓGICAS (9)
Regulation of cortical dendrite branchingSignaling by ROBO receptorsRegulation of expression of SLITs and ROBOsInactivation of CDC42 and RAC1Activation of RAC1
MECANISMO DE DOENÇA

Neurooculorenal syndrome

An autosomal recessive syndrome characterized by variable clinical features including congenital renal anomalies, neurodevelopmental defects, intellectual impairment, cardiac defects, and ocular anomalies. Some affected individuals present in utero with renal agenesis and structural brain abnormalities incompatible with life.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
25.0 TPM
Vagina
22.1 TPM
Cervix Ectocervix
20.1 TPM
Skin Not Sun Exposed Suprapubic
19.9 TPM
Cervix Endocervix
19.1 TPM
OUTRAS DOENÇAS (4)
neurooculorenal syndromepituitary hormone deficiency, combined or isolated, 8nystagmus, congenital, autosomal recessivepituitary stalk interruption syndrome
HGNC:10249UniProt:Q9Y6N7
GH1SomatotropinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Plays an important role in growth control. Its major role in stimulating body growth is to stimulate the liver and other tissues to secrete IGF1. It stimulates both the differentiation and proliferation of myoblasts. It also stimulates amino acid uptake and protein synthesis in muscle and other tissues

LOCALIZAÇÃO

Secreted

VIAS BIOLÓGICAS (3)
Synthesis, secretion, and deacylation of GhrelinProlactin receptor signalingGrowth hormone receptor signaling
MECANISMO DE DOENÇA

Growth hormone deficiency, isolated, 1A

An autosomal recessive, severe deficiency of growth hormone leading to dwarfism. Patients often develop antibodies to administered growth hormone.

EXPRESSÃO TECIDUAL(Tecido-específico)
Pituitária
53058.8 TPM
Cerebelo
5.3 TPM
Baço
4.4 TPM
Ovário
3.1 TPM
Testículo
2.8 TPM
OUTRAS DOENÇAS (4)
isolated growth hormone deficiency type IIshort stature due to growth hormone qualitative anomalyisolated growth hormone deficiency type IBisolated growth hormone deficiency type IA
HGNC:4261UniProt:P01241
LHX3LIM/homeobox protein Lhx3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Transcription factor. Recognizes and binds to the consensus sequence motif 5'-AATTAATTA-3' in the regulatory elements of target genes, such as glycoprotein hormones alpha chain CGA and visual system homeobox CHX10, positively modulating transcription; transcription can be co-activated by LDB2. Synergistically enhances transcription from the prolactin promoter in cooperation with POU1F1/Pit-1 (By similarity). Required for the establishment of the specialized cells of the pituitary gland and the n

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
Regulation of expression of SLITs and ROBOs
MECANISMO DE DOENÇA

Pituitary hormone deficiency, combined, 3

Combined pituitary hormone deficiency is defined as the impaired production of growth hormone and one or more of the other five anterior pituitary hormones. CPHD3 is characterized by a complete deficit in all but one (adrenocorticotropin) anterior pituitary hormone and a rigid cervical spine leading to limited head rotation.

EXPRESSÃO TECIDUAL(Tecido-específico)
Pituitária
89.7 TPM
Testículo
0.4 TPM
Skin Not Sun Exposed Suprapubic
0.1 TPM
Cerebelo
0.1 TPM
Cérebro - Hemisfério cerebelar
0.0 TPM
OUTRAS DOENÇAS (2)
non-acquired combined pituitary hormone deficiency with spine abnormalitieshypothyroidism due to deficient transcription factors involved in pituitary development or function
HGNC:6595UniProt:Q9UBR4
POU1F1Pituitary-specific positive transcription factor 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Transcription factor involved in the specification of the lactotrope, somatotrope, and thyrotrope phenotypes in the developing anterior pituitary. Specifically binds to the consensus sequence 5'-TAAAT-3'. Activates growth hormone and prolactin genes (PubMed:22010633, PubMed:26612202)

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

Pituitary hormone deficiency, combined, 1

Combined pituitary hormone deficiency is defined as the impaired production of growth hormone and one or more of the other five anterior pituitary hormones. CPHD1 is characterized by pleiotropic deficiencies of growth hormone, prolactin and thyroid-stimulating hormone, while the production of adrenocorticotropic hormone, luteinizing hormone, and follicle-stimulating hormone are preserved. In infancy severe growth deficiency from birth as well as distinctive facial features with prominent forehead, marked midfacial hypoplasia with depressed nasal bridge, deep-set eyes, and a short nose with anteverted nostrils and hypoplastic pituitary gland by MRI examination can be seen. Some cases present with severe intellectual disability along with short stature.

EXPRESSÃO TECIDUAL(Tecido-específico)
Pituitária
111.3 TPM
Cérebro - Hemisfério cerebelar
0.3 TPM
Cerebelo
0.2 TPM
Cervix Ectocervix
0.1 TPM
Fallopian Tube
0.1 TPM
OUTRAS DOENÇAS (4)
pituitary hormone deficiency, combined, 1hypothyroidism due to deficient transcription factors involved in pituitary development or functionisolated growth hormone deficiency type IIcombined pituitary hormone deficiencies, genetic form
HGNC:9210UniProt:P28069
HESX1Homeobox expressed in ES cells 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Required for the normal development of the forebrain, eyes and other anterior structures such as the olfactory placodes and pituitary gland. Possible transcriptional repressor. Binds to the palindromic PIII sequence, 5'-AGCTTGAGTCTAATTGAATTAACTGTAC-3'. HESX1 and PROP1 bind as heterodimers on this palindromic site, and, in vitro, HESX1 can antagonize PROP1 activation

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

Septooptic dysplasia

A clinically heterogeneous disorder defined by any combination of optic nerve hypoplasia, pituitary gland hypoplasia with panhypopopituitarism, and midline abnormalities of the brain, including absence of the corpus callosum and septum pellucidum.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
9.7 TPM
Linfócitos
4.2 TPM
Pituitária
2.4 TPM
Nervo tibial
2.3 TPM
Tireoide
2.3 TPM
OUTRAS DOENÇAS (5)
septooptic dysplasiaKallmann syndromehypothyroidism due to deficient transcription factors involved in pituitary development or functionpituitary stalk interruption syndrome
HGNC:4877UniProt:Q9UBX0
GLI2Zinc finger protein GLI2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Functions as a transcription regulator in the hedgehog (Hh) pathway (PubMed:18455992, PubMed:26565916). Functions as a transcriptional activator (PubMed:19878745, PubMed:24311597, PubMed:9557682). May also function as transcriptional repressor (By similarity). Requires STK36 for full transcriptional activator activity. Required for normal embryonic development (PubMed:15994174, PubMed:20685856) Involved in the smoothened (SHH) signaling pathway Involved in the smoothened (SHH) signaling pathway

LOCALIZAÇÃO

NucleusCytoplasmCell projection, cilium

VIAS BIOLÓGICAS (2)
Hedgehog 'off' stateHedgehog 'on' state
MECANISMO DE DOENÇA

Holoprosencephaly 9

A form of holoprosencephaly, a structural anomaly of the brain in which the developing forebrain fails to correctly separate into right and left hemispheres. It is a genetically and clinically heterogeneous disorder with a wide spectrum of severity, ranging from alobar holoprosencephaly with severe facial abnormalities, such as cyclopia and proboscis, to mild forms that include lobar or microform holoprosencephaly, without cerebral malformations and with mild craniofacial defects. HPE9 is characterized by defective anterior pituitary formation and pan-hypopituitarism, with or without overt forebrain cleavage abnormalities, and holoprosencephaly-like midfacial hypoplasia. HPE9 inheritance is autosomal dominant.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
22.1 TPM
Útero
11.2 TPM
Cervix Endocervix
10.1 TPM
Cervix Ectocervix
9.0 TPM
Fibroblastos
7.9 TPM
OUTRAS DOENÇAS (8)
postaxial polydactyly-anterior pituitary anomalies-facial dysmorphism syndromeholoprosencephaly 9combined pituitary hormone deficiencies, genetic formobsolete midline interhemispheric variant of holoprosencephaly
HGNC:4318UniProt:P10070
LHX4LIM/homeobox protein Lhx4Disease-causing germline mutation(s) (loss of function) inModerado
FUNÇÃO

May play a critical role in the development of respiratory control mechanisms and in the normal growth and maturation of the lung. Binds preferentially to methylated DNA (PubMed:28473536)

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
Regulation of expression of SLITs and ROBOs
MECANISMO DE DOENÇA

Pituitary hormone deficiency, combined, 4

Combined pituitary hormone deficiency is defined as the impaired production of growth hormone and one or more of the other five anterior pituitary hormones. CPHD4 is characterized by complete or partial deficiencies of growth hormone, thyroid-stimulating hormone, luteinizing hormone, follicle stimulating hormone and adrenocorticotropic hormone. Clinical features include short stature, cerebellar defects, and small sella turcica.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
5.2 TPM
Cerebelo
5.0 TPM
Cérebro - Hemisfério cerebelar
3.9 TPM
Pituitária
3.4 TPM
Tireoide
3.2 TPM
OUTRAS DOENÇAS (4)
short stature-pituitary and cerebellar defects-small sella turcica syndromehypothyroidism due to deficient transcription factors involved in pituitary development or functionpituitary stalk interruption syndromecombined pituitary hormone deficiencies, genetic form
HGNC:21734UniProt:Q969G2
OTX2Homeobox protein OTX2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Transcription factor probably involved in the development of the brain and the sense organs. Can bind to the bicoid/BCD target sequence (BTS): 5'-TCTAATCCC-3'

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (2)
Formation of the posterior neural plateFormation of the anterior neural plate
MECANISMO DE DOENÇA

Microphthalmia, syndromic, 5

Patients manifest unilateral or bilateral microphthalmia/clinical anophthalmia and variable additional features including pituitary dysfunction, coloboma, microcornea, cataract, retinal dystrophy, hypoplasia or agenesis of the optic nerve, agenesis of the corpus callosum, developmental delay, joint laxity, hypotonia, and seizures. Microphthalmia is a disorder of eye formation, ranging from small size of a single eye to complete bilateral absence of ocular tissues (anophthalmia). In many cases, microphthalmia/anophthalmia occurs in association with syndromes that include non-ocular abnormalities.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
24.4 TPM
Cerebelo
23.8 TPM
Substância negra
2.9 TPM
Hipotálamo
1.0 TPM
Testículo
0.7 TPM
OUTRAS DOENÇAS (8)
pituitary hormone deficiency, combined, 6syndromic microphthalmia type 5septooptic dysplasiacombined pituitary hormone deficiencies, genetic form
HGNC:8522UniProt:P32243
FOXA2Hepatocyte nuclear factor 3-betaDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Transcription factor that is involved in embryonic development, establishment of tissue-specific gene expression and regulation of gene expression in differentiated tissues. Is thought to act as a 'pioneer' factor opening the compacted chromatin for other proteins through interactions with nucleosomal core histones and thereby replacing linker histones at target enhancer and/or promoter sites. Binds DNA with the consensus sequence 5'-[AC]A[AT]T[AG]TT[GT][AG][CT]T[CT]-3' (By similarity). In embry

LOCALIZAÇÃO

NucleusCytoplasm

VIAS BIOLÓGICAS (7)
Positive Regulation of CDH1 Gene TranscriptionRegulation of gene expression in beta cellsFormation of axial mesodermFormation of definitive endodermDevelopmental Lineage of Multipotent Pancreatic Progenitor Cells
EXPRESSÃO TECIDUAL(Tecido-específico)
Estômago
26.8 TPM
Fígado
23.0 TPM
Pâncreas
17.4 TPM
Pulmão
14.2 TPM
Tireoide
5.7 TPM
OUTRAS DOENÇAS (1)
combined pituitary hormone deficiencies, genetic form
HGNC:5022UniProt:Q9Y261

Variantes genéticas (ClinVar)

419 variantes patogênicas registradas no ClinVar.

🧬 PROP1: NM_006261.5(PROP1):c.343-11C>G ()
🧬 PROP1: GRCh38/hg38 5q35.2-35.3(chr5:176144576-178014188)x1 ()
🧬 PROP1: GRCh37/hg19 5q35.2-35.3(chr5:176097556-180719789)x1 ()
🧬 PROP1: NM_006261.5(PROP1):c.374G>A (p.Arg125Gln) ()
🧬 PROP1: NM_006261.5(PROP1):c.593dup (p.Leu198fs) ()
Ver todas no ClinVar

Vias biológicas (Reactome)

82 vias biológicas associadas aos genes desta condição.

Peptide ligand-binding receptors G alpha (q) signalling events POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation Deactivation of the beta-catenin transactivating complex Transcriptional regulation of pluripotent stem cells Interleukin-4 and Interleukin-13 signaling Transcriptional Regulation by MECP2 Germ layer formation at gastrulation Formation of the anterior neural plate Formation of the posterior neural plate Specification of the neural plate border Transcriptional and post-translational regulation of MITF-M expression and activity Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition PPARA activates gene expression Phase I - Functionalization of compounds Endogenous sterols Xenobiotics Aryl hydrocarbon receptor signalling NPAS4 regulates expression of target genes PI3K Cascade PIP3 activates AKT signaling Signaling by FGFR1 amplification mutants Signaling by activated point mutants of FGFR1 FGFR1b ligand binding and activation FGFR1c ligand binding and activation FGFR1c and Klotho ligand binding and activation Constitutive Signaling by Aberrant PI3K in Cancer NCAM signaling for neurite out-growth Signal transduction by L1 Phospholipase C-mediated cascade: FGFR1 Downstream signaling of activated FGFR1 SHC-mediated cascade:FGFR1 PI-3K cascade:FGFR1 FRS-mediated FGFR1 signaling Negative regulation of FGFR1 signaling Signaling by FGFR1 in disease RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Signaling by plasma membrane FGFR1 fusions Epithelial-Mesenchymal Transition (EMT) during gastrulation Formation of paraxial mesoderm G alpha (s) signalling events Glucagon-type ligand receptors ER-Phagosome pathway MyD88:MAL(TIRAP) cascade initiated on plasma membrane Regulation of actin dynamics for phagocytic cup formation DAP12 signaling FCERI mediated Ca+2 mobilization G alpha (12/13) signalling events MyD88 deficiency (TLR2/4) IRAK4 deficiency (TLR2/4) RHO GTPases Activate WASPs and WAVEs G beta:gamma signalling through BTK FCGR3A-mediated phagocytosis Potential therapeutics for SARS Antigen activates B Cell Receptor (BCR) leading to generation of second messengers mRNA Splicing - Minor Pathway Netrin-1 signaling Signaling by ROBO receptors Activation of RAC1 Regulation of commissural axon pathfinding by SLIT and ROBO Inactivation of CDC42 and RAC1 Role of ABL in ROBO-SLIT signaling SLIT2:ROBO1 increases RHOA activity Regulation of cortical dendrite branching Regulation of expression of SLITs and ROBOs Prolactin receptor signaling Synthesis, secretion, and deacylation of Ghrelin Growth hormone receptor signaling Degradation of GLI2 by the proteasome Hedgehog 'off' state Hedgehog 'on' state GLI proteins bind promoters of Hh responsive genes to promote transcription RUNX2 regulates chondrocyte maturation Regulation of gene expression in beta cells Positive Regulation of CDH1 Gene Transcription Formation of axial mesoderm Formation of definitive endoderm Developmental Lineage of Pancreatic Acinar Cells Developmental Lineage of Pancreatic Ductal Cells Developmental Lineage of Multipotent Pancreatic Progenitor Cells

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
·Pré-clínico5
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 5 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Deficiências combinadas de hormônios hipofisários, formas genéticas

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

3 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

0 ensaios clínicos encontrados.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
138 papers (10 anos)

Mostrando amostra de 21 publicações de um total de 138

#1

Clinical and genetic basis of congenital gonadotropin deficiency.

Human reproduction open2026

What is the clinical and genetic overlap across subtypes of congenital gonadotropin (Gn) deficiency? This study reveals substantial clinical and genetic overlap among Gn deficiency disorders, with shared genetic and developmental features across congenital hypogonadotropic hypogonadism (CHH), combined pituitary hormone deficiency (CPHD), and syndromic forms of Gn deficiency. Congenital Gn deficiency includes a subset of hypogonadotropic hypogonadism (HH) and can result from defects at the level of the hypothalamus or the pituitary. It includes (i) CHH, further classified into normosmic CHH (nCHH) and Kallmann syndrome (KS); (ii) CPHD; and (iii) syndromic forms such as CHARGE syndrome and septo-optic dysplasia (SOD). The study included all probands with Gn deficiency recruited at a tertiary care center between 2011 and 2024 (n = 568), including 276 KS, 247 nCHH, 29 CPHD, and 16 syndromic Gn deficiency cases. All individuals underwent detailed clinical phenotyping followed by DNA sequencing. Genetic analysis focused on pathogenic (P) and likely pathogenic (LP) variants and variants of uncertain significance (VUS) within established CHH and CPHD genes. Oligogenicity was assessed in the CHH/syndromic HH cohort (n = 523) compared with controls from 1000 Genomes (n = 601). Genetic overlap among CHH, CPHD, and syndromic Gn deficiency was systematically investigated. Cleft lip/palate, dental agenesis, and ear abnormalities were recurrent across all Gn-deficient groups. Notably, some CPHD and SOD patients exhibited anosmia and a preserved Gn response to LH-releasing hormone (LHRH) stimulation, indicating a hypothalamic component to their HH. Rare variants in CHH genes were identified in 53% of KS probands (40% P/LP, 13% VUS) and 33% of nCHH probands (23% P/LP, 10% VUS). FGFR1, ANOS1, and PROKR2 were most frequently mutated in KS, while GNRHR, FGFR1, and KISS1R predominated in nCHH. Oligogenic inheritance was detected in 15% of CHH cases, with variants in FGFR1 being most commonly involved. Importantly, a substantial proportion (14%) of CHH patients without a molecular diagnosis carried rare variants predicted to be P or LP in genes typically associated with CPHD (e.g. ROBO1, BRAF, FAT2, and DCHS2). Conversely, several CHH-associated genes such as FGFR1 and FGF8, already implicated in CPHD, were also identified in patients with CPHD and syndromic GN deficiency, further supporting a shared genetic architecture between CHH and CPHD. N/A. Non-coding and copy number variants were not studied. Functional studies of the new candidate genes for CHH were not undertaken. This study highlights the importance of comprehensive clinical evaluation and broadened genetic testing in patients with Gn deficiency. This work was supported by the Swiss National Foundation (NP) (Grant No. 310030B_201275 to N.P.) and the Natural Science Foundation of Beijing (Grant No. 7244338 to Y.W.). The authors declare no competing interests.

#2

Biallelic pathogenic variants in POMC can cause combined pituitary hormonal deficiency associated with severe obesity.

European journal of endocrinology2025 Jun 30

Biallelic variants in the pro-opiomelanocortin gene (POMC) can cause hypocortisolism, hypopigmentation, and early-onset obesity. Following the identification of 2 patients of combined pituitary hormone deficiency (CPHD), we investigated the prevalence of this association among carriers of rare pathogenic or likely pathogenic (P/LP) POMC variants. This study is a case report and systematic literature review. Genetic analysis was conducted in a family with 2 cousins with childhood-onset obesity and CPHD. We assessed CPHD in carriers for biallelic pathogenic POMC variants using data from the literature and Human Gene Mutation Database. Clinical and biological data were collected, including pituitary axis involvement, obesity onset age, and pituitary imaging results. The 2 cousins, compound heterozygous for POMC variants, developed CPHD following initial hypocortisolism, with subsequent hypothyroidism, growth hormone deficiency, and hypogonadism. Among 41 patients with biallelic POMC variants identified in the literature, 20 had rare homozygous/compound heterozygous P/LP POMC variants and detailed endocrine evaluations. Of these, 40% presented with CPHD, always associated with early-onset severe obesity and hypocortisolism. Growth hormone deficiency was the most frequent (75%), followed by thyrotropic and gonadotropic deficiencies (62.5%). No anomalies were revealed in pituitary imaging. Two patients recovered the gonadotropic axis after treatment with the MC4R agonist. These findings underscore the potential for CPHD to occur in carriers of biallelic pathogenic POMC variants. Sequencing the full POMC, including coding and regulatory regions, is crucial in CPHD cases, alongside evaluating all pituitary axes in neonatal hypocortisolism. Beyond weight regulation, setmelanotide may modulate hypothalamic-pituitary function, with implications for fertility.

#3

Common and Uncommon Mouse Models of Growth Hormone Deficiency.

Endocrine reviews2024 Nov 22

Mouse models of growth hormone deficiency (GHD) have provided important tools for uncovering the various actions of GH. Nearly 100 years of research using these mouse lines has greatly enhanced our knowledge of the GH/IGF-1 axis. Some of the shared phenotypes of the 5 "common" mouse models of GHD include reduced body size, delayed sexual maturation, decreased fertility, reduced muscle mass, increased adiposity, and enhanced insulin sensitivity. Since these common mouse lines outlive their normal-sized littermates-and have protection from age-associated disease-they have become important fixtures in the aging field. On the other hand, the 12 "uncommon" mouse models of GHD described herein have tremendously divergent health outcomes ranging from beneficial aging phenotypes (similar to those described for the common models) to extremely detrimental features (such as improper development of the central nervous system, numerous sensory organ defects, and embryonic lethality). Moreover, advancements in next-generation sequencing technologies have led to the identification of an expanding array of genes that are recognized as causative agents to numerous rare syndromes with concomitant GHD. Accordingly, this review provides researchers with a comprehensive up-to-date collection of the common and uncommon mouse models of GHD that have been used to study various aspects of physiology and metabolism associated with multiple forms of GHD. For each mouse line presented, the closest comparable human syndromes are discussed providing important parallels to the clinic.

#4

Diagnosis and management of congenital hypopituitarism in children.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie2024 Apr

Hypopituitarism (or pituitary deficiency) is a rare disease with an estimated prevalence of between 1/16,000 and 1/26,000 individuals, defined by insufficient production of one or several anterior pituitary hormones (growth hormone [GH], thyroid-stimulating hormone [TSH], adrenocorticotropic hormone [ACTH], luteinizing hormone [LH], follicle-stimulating hormone [FSH], prolactin), in association or not with diabetes insipidus (antidiuretic hormone [ADH] deficiency). While in adults hypopituitarism is mostly an acquired disease (tumors, irradiation), in children it is most often a congenital condition, due to abnormal pituitary development. Clinical symptoms vary considerably from isolated to combined deficiencies and between syndromic and non-syndromic forms. Early signs are non-specific but should not be overlooked. Diagnosis is based on a combination of clinical, laboratory (testing of all hormonal axes), imaging (brain magnetic resonance imaging [MRI] with thin slices centered on the hypothalamic-pituitary region), and genetic (next-generation sequencing of genes involved in pituitary development, array-based comparative genomic hybridization, and/or genomic analysis) findings. Early brain MRI is crucial in neonates or in cases of severe hormone deficiency for differential diagnosis and to inform syndrome workup. This article presents recommendations for hormone replacement therapy for each of the respective deficient axes. Lifelong follow-up with an endocrinologist is required, including in adulthood, with multidisciplinary management for patients with syndromic forms or comorbidities. Treatment objectives include alleviating symptoms, preventing comorbidities and acute complications, and optimal social and educational integration.

#5

Comparison of clinical characteristics of a pediatric cohort with combined pituitary hormone deficiency caused by mutation of the PROP1 gene or of other origins.

Hormones (Athens, Greece)2024 Mar

The most commonly identified genetic cause of combined pituitary hormone deficiency (CPHD) is PROP1 gene mutations. The aim of the study was to compare selected clinical features of patients with CPHD caused by variants of the PROP1 gene (CPHD-PROP1) and patients with inborn CPHD of other etiology (CPHD-nonPROP1). The retrospective analysis included childhood medical records of 74 patients (32 female) with CPHD, including 43 patients (23 female) with the mutation in the PROP1 gene. Patients with CPHD-PROP1 compared to the CPHD-nonPROP1 presented with the following: significantly higher median birth weight (0.21 vs. - 0.29 SDS, p = 0.019), lower growth velocity within 3 years preceding growth hormone administration (- 2.7 vs. - 0.8 SDS, p < 0.001), higher mean maximal blood concentration of growth hormone within the stimulation process (1.2 vs. 1.08 ng/mL, p = 0.003), lower TSH (1.8 vs. 2.4 µIU/mL, p < 0.001), significantly lower prolactin concentrations (128 vs. 416.3 µIU/mL, p < 0.001), and less frequent typical signs of hypogonadism at birth in boys (n = 6; 30% vs. n = 12, 54%, p < 0.001). Secondary adrenal insufficiency was less frequent in CPHD-PROP1 (20 vs. 25 cases, p = 0.006) and occurred at a later age (13.4 vs. 10.4 years). MRI of the pituitary gland in CPHD-PROP1 revealed a small pituitary gland (21 cases), pituitary gland enlargement (eight cases), and one pituitary stalk interruption and posterior lobe ectopy, while it was normal in nine cases. Patients with the PROP1 mutations present a clinical picture significantly different from that of other forms of congenital hypopituitarism. Certain specific clinical results may lead to the successful identification of children requiring diagnostics for the PROP1 gene mutation.

Publicações recentes

Ver todas no PubMed

📚 EuropePMCmostrando 21

2026

Clinical and genetic basis of congenital gonadotropin deficiency.

Human reproduction open
2025

Biallelic pathogenic variants in POMC can cause combined pituitary hormonal deficiency associated with severe obesity.

European journal of endocrinology
2024

Common and Uncommon Mouse Models of Growth Hormone Deficiency.

Endocrine reviews
2024

Diagnosis and management of congenital hypopituitarism in children.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie
2024

Comparison of clinical characteristics of a pediatric cohort with combined pituitary hormone deficiency caused by mutation of the PROP1 gene or of other origins.

Hormones (Athens, Greece)
2024

Diagnosing and treating anterior pituitary hormone deficiency in pediatric patients.

Reviews in endocrine &amp; metabolic disorders
2023

Paraneoplastic isolated adrenocorticotropic hormone deficiency revealed after immune checkpoint inhibitors therapy: new insights into anti-corticotroph antibody.

Frontiers in immunology
2023

Spondyloenchondrodysplasia in five new patients: identification of three novel ACP5 variants with variable neurological presentations.

Molecular genetics and genomics : MGG
2022

Analysis of ProP1 Gene in a Cohort of Tunisian Patients with Congenital Combined Pituitary Hormone Deficiency.

Journal of clinical medicine
2022

Whole Exome Sequencing Points towards a Multi-Gene Synergistic Action in the Pathogenesis of Congenital Combined Pituitary Hormone Deficiency.

Cells
2021

Reassessment of predictive values of ACTH-stimulated serum 21-deoxycortisol and 17-hydroxyprogesterone to identify CYP21A2 heterozygote carriers and nonclassic subjects.

Clinical endocrinology
2021

Predictors of reproductive and non-reproductive outcomes of gonadotropin mediated pubertal induction in male patients with congenital hypogonadotropic hypogonadism (CHH).

Journal of endocrinological investigation
2021

Homozygous HESX1 and COL1A1 Gene Variants in a Boy with Growth Hormone Deficiency and Early Onset Osteoporosis.

International journal of molecular sciences
2020

Evolving pituitary hormone deficits in primarily isolated GHD: a review and experts' consensus.

Molecular and cellular pediatrics
2020

Development of the Pituitary Gland.

Comprehensive Physiology
2019

Clinical and Immunological Phenotype of Patients With Primary Immunodeficiency Due to Damaging Mutations in NFKB2.

Frontiers in immunology
2019

High Prevalence of Growth Plate Gene Variants in Children With Familial Short Stature Treated With GH.

The Journal of clinical endocrinology and metabolism
2019

The diagnosis and management of central hypothyroidism in 2018.

Endocrine connections
2017

Functional Characterization of Transient Receptor Potential (TRP) Channel C5 in Female Murine Gonadotropes.

Endocrinology
2017

Two novel LHX3 mutations in patients with combined pituitary hormone deficiency including cervical rigidity and sensorineural hearing loss.

BMC endocrine disorders
2015

Heterozygous deletion of FOXA2 segregates with disease in a family with heterotaxy, panhypopituitarism, and biliary atresia.

Human mutation

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Deficiências combinadas de hormônios hipofisários, formas genéticas.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Deficiências combinadas de hormônios hipofisários, formas genéticas

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Clinical and genetic basis of congenital gonadotropin deficiency.
    Human reproduction open· 2026· PMID 41873429mais citado
  2. Biallelic pathogenic variants in POMC can cause combined pituitary hormonal deficiency associated with severe obesity.
    European journal of endocrinology· 2025· PMID 40513101mais citado
  3. Common and Uncommon Mouse Models of Growth Hormone Deficiency.
    Endocrine reviews· 2024· PMID 38853618mais citado
  4. Diagnosis and management of congenital hypopituitarism in children.
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie· 2024· PMID 38538470mais citado
  5. Comparison of clinical characteristics of a pediatric cohort with combined pituitary hormone deficiency caused by mutation of the PROP1 gene or of other origins.
    Hormones (Athens, Greece)· 2024· PMID 38147295mais citado
  6. New insights into Oliver-McFarlane syndrome: adrenocortical hypofunction and variable expressivity in a Chinese sibling pair.
    J Pediatr Endocrinol Metab· 2026· PMID 41846525recente
  7. GH Response to Glucagon in Transition: Role of BMI and Etiology in Childhood-Onset GH Deficiency.
    J Clin Endocrinol Metab· 2026· PMID 41521526recente
  8. Webb-Dattani syndrome in a 17-year-old girl.
    Endocrinol Diabetes Metab Case Rep· 2025· PMID 41363294recente
  9. Genetic requirement for Esrp1 and Esrp2 in vertebrate pituitary morphogenesis.
    Development· 2025· PMID 41111330recente
  10. Compound heterozygous ROBO1 gene variants in a neonate with congenital hypopituitarism, dysmorphic features and midline abnormalities: a case report and review of the literature.
    J Pediatr Endocrinol Metab· 2025· PMID 40884218recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:95494(Orphanet)
  2. MONDO:0013099(MONDO)
  3. GARD:10602(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Artigo Wikipedia(Wikipedia)
  7. Q922411(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Deficiências combinadas de hormônios hipofisários, formas genéticas
Compêndio · Raras BR

Deficiências combinadas de hormônios hipofisários, formas genéticas

ORPHA:95494 · MONDO:0013099
Prevalência
Unknown
Herança
Autosomal dominant, Autosomal recessive, X-linked recessive
CID-10
E23.0 · Hipopituitarismo
CID-11
Início
Infancy, Neonatal
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C0020635
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades